Ad Code: Tecentriq - Display Banners - MAY - 281454

Findings suggest that adding lurbinectedin to atezolizumab for first-line maintenance therapy benefits patients with extensive-stage small cell lung cancer.

New findings from the ADRIATIC trial revealed that distinct immune biomarkers may help identify patients with limited-stage small-cell lung cancer who are more likely to experience long-term progression-free survival after chemoradiotherapy.

Outpatient tarlatamab administration for relapsed small cell lung cancer was feasible and safe with proper monitoring, according to findings presented at ASCO.

Real-world data show first-line chemo-immunotherapy improves survival and response rates over chemo alone in extensive-stage SCLC, supporting its broader use.

Lurbinectedin showed clinical benefit across therapy lines in SCLC, with best responses seen in later lines and with prior immunotherapy exposure.